74.3 F
New York
Friday, August 12, 2022

Date:

Share:

Grünenthal to license osteoarthritis pain treatment to Shionogi in Japan in deal of up to > $ 500 million

Related Articles

Consumers Should Compare Medicare Drug Plans Advises Association

Los Angeles, CA, August 11, 2022 --(PR.com)-- Many of the 50 million Americans with Medicare prescription drug plans fail to compare available options reports the...

Alternative Liquidity Capital Announces Offer to Purchase Shares in LookSmart Group, Inc.

Minnetonka, MN, August 10, 2022 --(PR.com)-- Alternative Liquidity Capital has announced an offer to purchase up to 21,000 shares in LookSmart Group, Inc. (the “Company”)....

Crypto Lists Reach 150 Deposit Methods

London, United Kingdom, August 10, 2022 --(PR.com)-- Cryptolists.com seeks to fill in this gap for investors and crypto followers by showing an exceptionally wide range...

Aachen, Germany – 4 August 2022 – Grünenthal and Shionogi announced today that they have entered into a licensing agreement for Grünenthal’s investigational medicine Resiniferatoxin (“RTX”). Shionogi obtained the exclusive rights to commercialise Grünenthal’s asset in Japan for pain associated with osteoarthritis of the knee.

RTX is currently in Phase III of clinical development for the treatment of patients with moderate to severe pain associated with knee osteoarthritis. Osteoarthritis, a progressive and often painful joint disease, is an indication with high unmet medical need. If approved, RTX could become a well-tolerated, non-opioid therapy option for patients, providing long-lasting pain relief and functional improvement of the affected knee joints.

Under the terms of the agreement, Shionogi will obtain the exclusive commercialisation rights for RTX in Japan for a total consideration of up to $ 525 million…

Read more…

Popular Articles